RxDoctor Payments Data

Amber Moryl, PA

Physician Assistant · Chino, CANPI 1467880229

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by GSK at 29.6% of the total. Reporting peaked in 2024 at $220 and has fallen 81.8% since, to $40 in 2025.

$517in general payments, 2019–2025

Across 20 payments — averaging $25.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$153
  • Lilly USA, LLC$138
  • Novo Nordisk$66
  • Pfizer$52
  • Abbott$52
  • Boston Scientific$31
  • plus $25 from 1 others

What the payments were for

  • Food & beverage$517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK8$153
Lilly USA, LLC3$138
Novo Nordisk3$66
Pfizer2$52
Abbott2$52
Boston Scientific1$31
Phadia US Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$517 in reported general payments places this provider in the 60th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$13,954
Medicare patients
71
Services billed
1,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$46,526
EliquisApixaban31$28,363
TrulicityDulaglutide19$25,683
FarxigaDapagliflozin Propanediol15$22,951
Janumet XrSitagliptin Phos/Metformin Hcl11$7,268
XareltoRivaroxaban13$6,801
Levothyroxine Sodium117$1,685
Atorvastatin Calcium191$1,571
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen109$1,446
Losartan Potassium94$960
Venlafaxine Hcl ErVenlafaxine Hcl15$871
Estradiol14$864
Gabapentin63$851
Albuterol Sulfate HfaAlbuterol Sulfate48$850
Glipizide ErGlipizide33$820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$66$46,52640 claims
PfizerEliquis$52$28,36331 claims
Lilly USA, LLCTrulicity$138$25,68319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Chino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →